论文部分内容阅读
目的:探讨沙格雷酯治疗2型糖尿病伴下肢动脉硬化闭塞症(ASO)患者的临床疗效。方法:选择2014年4月~2015年5月我院2型糖尿病伴下肢ASO患者80例,给予口服沙格雷酯100 mg,3次/日,连续8周,监测治疗前后患肢的症状与体征、双下肢动脉峰值血流速度、血糖、血脂及血液流变学等指标的变化。结果:口服沙格雷酯8周后,患者疼痛感、冷感、间歇性踱行、麻木感及下肢溃疡等主观症状有效率均大于91%,临床总有效率为93.75%。治疗后患者左、右下肢动脉血管直径与治疗前比较,差异无统计学意义(P>0.05),但左、右下肢动脉峰值血流速度比治疗前显著降低,差异有统计学意义(P<0.05)。治疗后患者的甘油三酯、总胆固醇、低密度脂蛋白、全血高切黏度及全血低切黏度比治疗前降低,差异有统计学意义(P<0.05)。结论:沙格雷酯可改善2型糖尿病伴下肢ASO患者的症状,降低双下肢动脉峰值血流速度,临床疗效确切,值得临床推广应用。
Objective: To investigate the clinical efficacy of sarpogrelate in the treatment of type 2 diabetes mellitus (ASO) patients with lower extremity arteriosclerosis obliterans. Methods: From April 2014 to May 2015, 80 ASO patients with type 2 diabetes mellitus and lower extremities in our hospital were treated with oral sagereptrel 100 mg for 3 weeks for 8 weeks. The symptoms and signs of the affected limbs were monitored before and after treatment , The lower extremity arterial peak blood flow velocity, blood glucose, blood lipids and hemorheology and other indicators of change. Results: After 8 weeks of oral administration of sarpogrelate, the subjective symptom such as pain, cold sensation, intermittent pacing, numbness and leg ulcer were all higher than 91%. The total clinical effective rate was 93.75%. After treatment, the diameters of left and right lower extremity arteries were not significantly different from those before treatment (P> 0.05), but the left and right lower extremity arteries peak velocity were significantly lower than those before treatment (P < 0.05). After treatment, the triglyceride, total cholesterol, low density lipoprotein, whole blood high shear viscosity and whole blood low shear viscosity were lower than before treatment, the difference was statistically significant (P <0.05). Conclusion: Saregrame can improve the symptoms of type 2 diabetes mellitus patients with lower extremity ASO, and reduce the peak blood flow velocity of the lower extremities. The clinical effect is exact and worthy of clinical application.